Eur Urol Suppl 2010;9(2):284 901 SOMATOSTATIN ANALOG IN THE TREATMENT OF ANDROGEN–INDEPENDENT PROSTATE CANCER BEFORE AND AFTER CHEMOTHERAPY 1 Moscow Hertzen Oncology Institute, Dept. of Oncourology, Moscow, Russia, 2 Russian Scientific Center of Radiology, Dept. of Urology, Moscow, Russia, 3 Research Institute of Urology, Dept. of Urology, Moscow, Russia Introduction & Objectives: Material & Methods: Results: Conclusions: 902 WITHDRAWN 903 IMPACT OF ZOLEDRONIC ACID ON FRACTURES AND MORTALITY IN PATIENTS WITH PROSTATE CANCER AND BONE METASTASES 1 I3 Innovus, Dept. of Health Economics and Outcomes Research, Eden Prairie, United States of America, 2 Novartis Pharma Corporation, Dept. of Health Economics and Outcomes Research, Florham Park, United States of America Introduction & Objectives: Material & Methods: Results: Results: Conclusions: 900 PHASE II STUDY OF A COMBINATION OF A LHRH ANALOGUE, DEZAMETHASONE AND A SOMATOSTATIN ANALOGUE (SM-A) VERSUS A LHRH ANALOGUE WITH DEXAMETHASONE IN REFRACTORY PROSTATE CANCER PATIENTS 1 Hospital Desterro, Dept. of Urology, Lisbon, Portugal, 2 Centro Hospitalar de Lisboa Central, Dept. of Urology, Lisbon, Portugal, 3 St. Bartholomew’s Hospital, Dept. of Urology, London, United Kingdom, 4 Comenius University, Dept. of Urology, Bratislava, Slovakia Introduction & Objectives: Material & Methods: Results: Conclusions: